Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
EClinicalMedicine
; 63: 102160, 2023 Sep.
Article
en En
| MEDLINE
| ID: mdl-37649806
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Guideline
Idioma:
En
Año:
2023
Tipo del documento:
Article